玻璃体腔注射雷珠单抗治疗新生血管性眼病的临床疗效及安全性分析

Clinical Study and Safety of Intraventricular Injection with Lebezumab in the treatment Neonatal Vascular Eye Disease

目的:探讨玻璃体腔注射雷珠单抗治疗新生血管性眼病的临床效果及安全性分析。方法:选择2016年2月至2017年12月78例脉络膜新生血管患者,按随机数表法分为对照组和研究组,每组39例。对照组予以维替芬光动力疗法(PDT)治疗,研究组于玻璃体腔内注射雷珠单抗治疗。比较两组临床疗效,最佳矫正视力,黄斑部中心凹视网膜厚度(CRT),和不良反应发生情况。结果:研究组治疗有效率高于对照组,比较有统计学差异(P<0.05)。治疗前,两组最佳矫正视力和CRT比较无差异(P>0.05);治疗后1月、治疗后6月两组最佳矫正视力均上升,CRT均下降,研究组改变更明显,两组最佳矫正视力及CRT在治疗后1月、治疗后6月的比较均有统计学差异(P<0.05)。对照组和研究组不良反应发生率分别为10.26%(4/39)和12.82%(5/39),组间比较无差异(P>0.05)。结论:玻璃体腔内注射雷珠单抗治疗脉络膜新生血管的疗效突出,能够提高患者视力,改善视网膜水肿,值得临床推广。

Objective： To explore the clinical effect and safety of intraventricular injection with lebezumab in the treatment neonatal vascular eye disease. Methods： 78 patients with choroidal neovascularization admitted to our hospital from February 2016 to December 2017 were randomly divided into control group andstudy group, 39 cases in each group. The control group was treated with vitrified photodynamic therapy（PDT）, and the study group was treated with intravitreal injection of razomab. The clinical efficacy, best corrected visual acuity, macular foveal retinal thickness （CRT）, and adverse reactions were compared betweenthe two groups. Results： The effective rate of the study group was higher than that of the control group, andthe difference was statistically significant （P〈0.05）. There was no difference in the best corrected visual acuity and CRT between the two groups before treatment （P〉0.05）. The best corrected visual acuity and CRT ofthe two groups increased in 1 month and decreased in 6 months after treatment, and the change was more obvious in the study group. There were significant differences in the best corrected visual acuity and CRT betweenthe two groups in 1 month and 6 months after treatment （P〈0.05）. The incidence of adverse reactions in thecontrol group and the study group were 10.26% （4 / 39） and 12.82% （5 / 39）, respectively. There was no significant difference between the two groups （P 〉 0.05）. Conclusion： Intravitreal injection of razomab in thetreatment of choroidal neovascularization has a prominent effect. And it can improve visual acuity, improve retinal edema, worthy of clinical promotion.